RVRosauro Varo

Rosauro Varo

*This is an algorithmically generated author record based on publicly available information.

Rosauro Varo has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Quique Bassat

    Affiliations Centro de Investigação em Saúde de Manhiça [CISM], Maputo, Mozambique, ISGlobal - Hospital Clínic, Universitat de Barcelona, Barcelona, Spain, Institutó Catalana de Recerca i Estudis Avançats [ICREA], Barcelona, Spain, Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Barcelona, Spain, CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain

    3 shared publications
  • Lola Madrid

    Affiliations Department of Infectious Disease Epidemiology and International Health, London School of Hygiene and Tropical Medicine, London, United Kingdom, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia

    2 shared publications
  • Ana Marta Valente

    Ctr Invest Saude Manhica, Maputo, Mozambique

    1 shared publication
  • Antonio Sitoe

    Centro de Investigação em Saúde de Manhiça, Rua 12, Vila da Manhiça, 1929, Maputo, Mozambique

    1 shared publication
  • Antonio Sitoe

    Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique

    1 shared publication
  • Dianna M. Blau

    Ctr Dis Control & Prevent, Atlanta, GA USA

    1 shared publication

Latest Publications

  • Open Access

    Sneathia amniiand Maternal Chorioamnionitis and Stillbirth, Mozambique

    by Pio Vitorino, Rosauro Varo, Paola Castillo, Juan Carlos Hurtado, Fabiola Fernandes, Ana Marta Valente, Rita Mabunda, Sibone Mocumbi, Joy M. Gary, Tiffany G. Jenkinson, et al.

    We report a case of Sneathia amnii as the causative agent of maternal chorioamnionitis and congenital pneumonia resulting in a late fetal death in Mozambique, with strong supportive postmortem molecular and histopathological confirmation. This rare, fastidious gram-negative coccobacillus has been reported to infrequently cause abortions, stillbirths, and neonatal infections.


  • Open Access

    Continuous Glucose Monitoring in Resource-Constrained Settings for Hypoglycaemia Detection: Looking at the Problem from the Other Side of the Coin

    by Rubao Bila, Rosauro Varo, Lola Madrid, Antonio Sitoe, Quique Bassat

    The appearance, over a decade ago, of continuous glucose monitoring (CGM) devices has triggered a patient-centred revolution in the control and management of diabetes mellitus and other metabolic conditions, improving the patient’s glycaemic control and quality of life. Such devices, the use of which remains typically restricted to high-income countries on account of their elevated costs, at present show very limited implantation in resource-constrained settings, where many other urgent health priorities beyond diabetes prevention and management still need to be resolved. In this commentary, we argue that such devices could have an additional utility in low-income settings, whereby they could be selectively used among severely ill children admitted to hospital for closer monitoring of paediatric hypoglycaemia, a life-threatening condition often complicating severe cases of malaria, malnutrition, and other common paediatric conditions.


  • Open Access

    Adjunctive therapy for severe malaria: a review and critical appraisal

    by Rosauro Varo, Valerie M. Crowley, Antonio Sitoe, Lola Madrid, Lena Serghides, Kevin C. Kain, Quique Bassat

    Despite recent efforts and successes in reducing the malaria burden globally, this infection still accounts for an estimated 212 million clinical cases, 2 million severe malaria cases, and approximately 429,000 deaths annually. Even with the routine use of effective anti-malarial drugs, the case fatality rate for severe malaria remains unacceptably high, with cerebral malaria being one of the most life-threatening complications. Up to one-third of cerebral malaria survivors are left with long-term cognitive and neurological deficits. From a population point of view, the decrease of malaria transmission may jeopardize the development of naturally acquired immunity against the infection, leading to fewer total cases, but potentially an increase in severe cases. The pathophysiology of severe and cerebral malaria is not completely understood, but both parasite and host determinants contribute to its onset and outcomes. Adjunctive therapy, based on modulating the host response to infection, could help to improve the outcomes achieved with specific anti-malarial therapy. In the last decades, several interventions targeting different pathways have been tested. However, none of these strategies have demonstrated clear beneficial effects, and some have shown deleterious outcomes. This review aims to summarize evidence from clinical trials testing different adjunctive therapy for severe and cerebral malaria in humans. It also highlights some preclinical studies which have evaluated novel strategies and other candidate therapeutics that may be evaluated in future clinical trials.